Key references: Drugs to avoid or to use with caution in myasthenia gravis

Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. Mt Sinai J Med 2002;69(1-2):31–7. https://www.ncbi.nlm.nih.gov/pubmed/11832968
Aspen Pharmacare Australia. Tracrium injection (atracurium besylate) [product information]. eMIMS; 2013.
Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 1997;17(6):1220–32. https://www.ncbi.nlm.nih.gov/pubmed/9399604
Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand 2012;56(1):17–22. https://www.ncbi.nlm.nih.gov/pubmed/22091897
Bonanni L, Vestra M, Presotto F. Can we say that modern radiologic contrast agents are safe in myasthenia gravis? Muscle Nerve 2015;51(5):782–3. https://www.ncbi.nlm.nih.gov/pubmed/25656739
Dalakas MC. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business. Neurology 2016;87(4):350–1. https://www.ncbi.nlm.nih.gov/pubmed/27358340
Howard JF, editor. Myasthenia gravis: a manual for the health care provider. St. Paul, MN: Myasthenia Gravis Foundation of America; 2009. https://myasthenia.org/wp-content/uploads/Portals/0/Provider%20Manual_ibook%20version.pdf
Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015;33(33):e122–4. https://www.ncbi.nlm.nih.gov/pubmed/24778401
Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011;34(10):839–47. https://www.ncbi.nlm.nih.gov/pubmed/21879778
Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16(4):589–93. https://www.ncbi.nlm.nih.gov/pubmed/24482447
Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 2015;52(2):307–8. https://www.ncbi.nlm.nih.gov/pubmed/25759003
Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and myasthenia gravis (A reference for health care professionals). St. Paul, MN: Myasthenia Gravis Foundation of America; 2012. http://myasthenia.org/HealthProfessionals/EducationalMaterials.aspx
Mehrizi M, Pascuzzi RM. Complications of radiologic contrast in patients with myasthenia gravis. Muscle Nerve 2014;50(3):443–4. https://www.ncbi.nlm.nih.gov/pubmed/24677227
Merck Sharp & Dohme (Australia). Norcuron (vecuronium bromide) [product information]. eMIMS; 2014.
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26(12):2375–91. https://www.ncbi.nlm.nih.gov/pubmed/26371282
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419–25. https://www.ncbi.nlm.nih.gov/pubmed/27358333
Somashekar DK, Davenport MS, Cohan RH, Dillman JR, Ellis JH. Effect of intravenous low-osmolality iodinated contrast media on patients with myasthenia gravis. Radiology 2013;267(3):727–34. https://www.ncbi.nlm.nih.gov/pubmed/23360741